NCT01395797View on ClinicalTrials.gov

Pioglitazone for Heroin and for Nicotine Dependence

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions
Heroin DependenceNicotine Dependence
Interventions
DRUG

PIO

0, 15, and 45 mg per day.

DRUG

Placebo

Placebo

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

Sponsors

Collaborators (1)

Omeros Corporation
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Omeros Corporation

INDUSTRY

lead

New York State Psychiatric Institute

OTHER